PATENT CLAIM ANALYSIS

Application Number: 16363206
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "282000"]

Abstract:
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

Claim (Index 22):
A method of treating overweight or obesity, the method comprising administering to a patient in need thereof a therapeutically effective amount of bupropion, or a pharmaceutically acceptable salt thereof, and naltrexone, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.72881
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11356839', '10828795', '15276600', '14326075', '11602571']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6806155715831501
- 35 USC 102 Novelty (BERT): 0.5002741661462818
- Combined Prediction Score: 0.6625814310394633
- Mean Citation Score: 231.977296
- Max Citation Score: 250.31992
- Similarity Product: 198.31542880194664

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test